regimen. Recipient mice were treated with anti-CD3, anti-CD4, low-dose total body irradiation (3 to 6 Gy TBI) and induction of mixed hematopoietic chimerism and donor-specific tolerance in animal models. This procedure, however, fully mismatched or haploidentical donor bone marrow cells. Stable multilineage chimerism and specific T-cell nonre-is inapplicable in clinical transplantation using cadaveric donors due to the interval (1 week to 7 months) between toler-sponsiveness developed. Donor skin grafts were permanently accepted. These results suggest that this single day ance induction and organ transplantation. For clinical use, it is essential that allografts be placed at the time of bone protocol has clear potential for application in both cadaveric and living-related organ transplantation. marrow transfusion. In the present study, we performed skin transplantation within 1 hour after a nonlethal conditioning ᭧ 1997 by The American Society of Hematology.
I
Therefore, in the present study, we have shortened this time interval and performed skin transplantation within 1 hour MPROVEMENTS in immunosuppressive protocols largely account for the current level of success observed in organ transplantation. However, this success has a reverse following conditioning. We report here that stable multilineage mixed chimerism and permanent donor-specific toler-side. It means life-long treatment of patients with immunosuppressive therapy, which is associated with many, some-ance for skin can be successfully achieved across multiple histocompatibility barriers without using a lethal condition-times serious, side-effects. In addition, the continuous risk of chronic rejection, which is difficult to treat, remains. For ing approach. Furthermore, this regimen does not require prolonged treatment of the host before transplantation, mak-these reasons, one of the major goals in transplantation immunology is the search for methods of inducing donor-spe-ing it even more attractive for clinical application. cific tolerance to transplantation antigens.
MATERIALS AND METHODS

It has been demonstrated in several animal models that
Animals. Eight-to 14- week-old male mice with different H-2 the establishment of mixed hematopoietic chimerism through This well-tolerated, nontoxic protocol results in the developwith 10% heat-inactivated fetal calf serum (FCS). Erythrocytes were ment of stable mixed chimerism and permanent transplantalysed with an ammonium chloride buffer. Bone marrow cells were tion tolerance without any clinical evidence of graft-versusdepleted of T cells by treatment with anti-Thy-1.2 monoclonal antihost-disease (GVHD). 9,10 body (F7D5; Serotec, Wiesbaden, Germany) and complement (low So far, the clinical application of our and other experimentox M rabbit complement; Cedarlane, Hornby, Ontario, Canada), tal models has been hampered by the relatively long interval and contained less than 0.2% T cells as measured by flow cytometry between tolerance induction and the actual transplantation, analysis. Recipient animals were reconstituted with 15.10 6 allogeneic bone marrow cells in 0.25 mL of saline containing 5% heat-inacti-which varies in different models from 1 week to 7 months. 1-10 vated autologous serum via caudal vein injection.
Conditioning regimen. B10 mice were treated once with 3 or 6 Gy TBI and a single dose of 400 mg anti-CD3 intraperitoneal (IP).
From the Department of Transplantation Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service,
For reconstitution, 15.10 6 (6.10 8 /kg) haploidentical (B10 1 B10.D2)F1 or fully mismatched B10.D2 bone marrow cells or a Amsterdam; and the Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam, The Netherlands. mixture of 15.10 6 B10.D2 and 5.10 6 (2.10 8 /kg) syngeneic bone marrow cells were injected intravenously (IV The publication costs of this article were defrayed in part by page tolerance, as previously shown. 9,10 Skin transplantation. Within 1 hour after completing the condi-charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. section 1734 solely to tioning regimen, tail skin transplantation was performed. Each recipient mouse was given a control B10 (syngeneic), a B10.D2 or (B10 indicate this fact.
᭧ 1997 by The American Society of Hematology. 1 B10.D2)F1 (donor), and a B10.BR (third party) skin graft. The grafts were inspected three times a week and considered to be re-0006-4971/97/8907-0028$3.00/0 jected when no viable donor skin was detectable. Second donor-type skin grafts were transplanted 4 months after the first skin grafts.
Flow cytometry analysis. Engraftment of donor cells was determined by two-color flow cytometry using a FACScan (Becton Dickinson, Mountain View, CA). All procedures were performed in phosphate-buffered saline (PBS) containing 0.2% bovine serum albumin and 0.05% sodium azide. Fluorescence data were collected by using logarithmic amplification on 10 4 viable cells as determined by forward light scatter intensity. To quantify chimerism, cells were stained with H-2D d -fluorescein isothiocyanate (FITC) and H-2K bphycoerythrin (PE) (Pharmingen, San Diego, CA). For lineage analysis of chimerism, PE-conjugated MoAbs against T cells (Thy-1.2, CD4, and CD8), B cells (B220), granulocytes (GR-1), and macrophages (MAC-1) (all from Pharmingen) were used in double staining with antidonor antibody (H-2D d -FITC).
Fig 1. Percentages of donor () (H-2 d )-and host (ᮀ) (H-2 b )-derived
Cell-mediated lympholysis (CML). CML assays were performed cells in peripheral blood of mixed chimeras measured 4 months after as described previously. 9 Radioactivity was measured in a gamma following reconstitution. Cells from the spleen, lymph nodes,
RESULTS
peripheral blood, bone marrow, and thymus were collected and screened by flow cytometry. The percentage of chime-Induction of stable mixed chimerism. To develop a model for clinical use, we have performed our tolerance rism was determined, as well as the contribution of donorderived lymphoid (T, both CD4 and CD8 subsets, and B inducing protocol and the actual allotransplantation on the same day. B10 (H-2 b ) recipient mice were treated with anti-cells) and myeloid (granulocytes and macrophages) cells. Results of typing spleen, lymph nodes, and peripheral blood CD3 and anti-CD4 MoAbs, 6 Gy TBI, and 15.10 6 fully allogeneic B10.D2 (H-2 d ) bone marrow cells. To maintain of haploidentical conditioned mice are shown in Table 2 and Fig 2. Donor-type cells were also clearly present in bone the host own immune repertoire as much as possible, we also reduced the level of chimerism by transfusion with a marrow and in the thymus (data not shown). Data obtained from fully MHC disparate conditioned mice were compara-combination of 5.10 6 syngeneic and 15.10 6 allogeneic Tcell depleted bone marrow cells. Within 1 hour following ble.
In conclusion, all analyzed chimeric mice showed multilineage donor-chimerism in the lymphoid tissues and the reconstitution, treated animals received skin grafts of recipient (B10), donor (B10.D2) and third party (B10.BR, H-2 k ) periphery. The level of chimerism induced was dependent on the conditioning regimen (see also Fig 1 and Table 1 ). origin. The presence of donor-type cells was measured by fluorescence-activated cell sorting (FACS) analysis on day Absolute correlation between substantial levels of mixed chimerism and permanent transplantation tolerance. To 49 and day 119, just before the second skin transplantation. Stable mixed chimerism was induced in five of six mice examine donor-specific unresponsiveness in vivo, all mice received host, donor, and third party skin grafts directly conditioned with a mixture of syngeneic and allogeneic bone marrow cells (Fig 1) . As shown before, mice transfused following bone marrow transfusion. Second skin transplantations were performed 4 months later. with allogeneic bone marrow cells were repopulated almost completely with cells of donor origin. 9,10 No persistent donor Most importantly, in all recipients, there was an absolute correlation between a substantial level of chimerism and bone marrow engraftment was seen after omission of TBI, anti-CD3, or allogeneic bone marrow cells from our condi-tolerance. All chimeric mice accepted host-type and first and second donor-type skin grafts permanently, without evidence tioning regimen (data not shown). 9 Because of the prospective HLA matching policies wide-of rejection (Fig 3 and Table 1 ). In contrast, donor-type skin grafts were rapidly rejected by nonchimeric control animals. spread in kidney transplant centers, kidney transplantation across a full HLA disparity does not occur frequently. There-Tolerance induction was specific, as third party (B10.BR) skin grafts were rejected by all mice. Furthermore, chimeras fore, we also tested a haploidentical donor-recipient combination. In this more clinical relevant situation, especially to appeared healthy without stigmata of GVHD. Thus, we clearly show that a combination of a sublethal living-related transplantations, even lower doses of TBI (3 Gy) can be used. All B10 (H-2 b ) mice receiving MoAbs dose of TBI, anti-T-cell MoAbs, and MHC incompatible bone marrow cells can ensure permanent tolerance to simul-(B10xB10.D2)F1 (H-2 b/d ), T-cell depleted bone marrow cells, and 3 or 6 Gy TBI showed stable mixed chimerism taneously transplanted allogeneic skin of the bone marrow donor strain. (Table 1) .
Multilineage chimerism. To determine engraftment of Donor-specific unresponsiveness in vitro. Another important criterion for permanent or classical tolerance induc-donor-type hematopoietic cells in conditioned mice, one representative animal of each group was killed 9 to 12 months tion is immunologic tolerance to host and donor antigens AID Blood 0047 / 5h31$$$921 02-27-97 16:36:22 blda WBS: Blood chimerism through bone marrow transfusion provides an efand reactivity to third party antigens in vitro. Therefore, fective means for the induction of tolerance across MHC splenocytes from mixed chimeras were examined using a barriers. 1-10 However, for clinical application in cadaveric cellular cytotoxicity assay. As shown in Fig 4, spleen cells organ transplantation, the delay between conditioning and from mixed chimeras were unresponsive to either donor the actual allotransplantation has to be eliminated because (B10.D2) or host-type (B10) target cells, whereas the cytoorgans can only be preserved for a limited amount of time. toxic T lymphocyte (CTL) response against third party In addition, in living-related transplantation, simultaneous (B10.BR) cells remained obviously present. Similarly, spleconditioning and organ transplantation would shorten the nocytes isolated from semiallogeneic-conditioned chimeric donation and transplantation protocols. In the present murine mice failed to lyse either host or donor (F1) targets, but study, we have performed the conditioning regimen and showed CTL reactivity to third-party targets (data not transplantation across major MHC barriers on the same day. shown). In contrast, lymphocytes from untreated control ani-Previously, we showed that sublethally irradiated mice mals exhibited a vigorous reactivity against donor, as well transfused across a fully allogeneic barrier were specifically as third party targets (Fig 4) . tolerant to both donor and recipient antigens, and yet fully reactive to third party antigens. 9,10 However, in lethally irra-DISCUSSION diated and fully allogeneic reconstituted mice, significant The ultimate goal in transplantation medicine is to achieve deficiency in primary humoral responses 12, 13 and deficient successful organ and tissue transplantation without the need cellular immune responses to intracellular pathogens 14 were for continuous immune suppression. We and others have demonstrated. Furthermore, in clinical allogeneic bone mardemonstrated previously that development of stable mixed row transplantation, complete reconstitution with donor-type cells creates a great risk for the development of GVHD. To minimize these risks, we tried to reduce the level of chimerism in our murine model. 10 In this way, we would be able 
anti-T-cell MoAbs and bone marrow cells or by adding
Control host 0.1 0.2 0.4 syngeneic bone marrow cells. 10 As we discussed before, 10 The results presented here clearly demonstrate that skin transplantation can be performed successfully directly following donor-specific bone marrow transfusion. We have shown before 9,10 that conditioned mice permanently accepted fully mismatched or, with more clinical relevance, haploidentical skin allografts transplanted 2 months (first graft) and 6 months (second graft) after conditioning. The establishment of stable mixed chimerism was confirmed by the presence of both donor-and host-derived cells in lymphoid organs and the periphery, 2, 4, and 9 months after conditioning. This lasting chimerism, as well as the presence of donortype cells in both lymphoid (T and B cells) and myeloid (macrophages and granulocytes) lineages, suggest that engraftment of donor hematopoietic stem cells has occurred.
A very important observation is that our single day protocol results in 'real' or classical transplantation tolerance. All chimeric mice showed specific T-cell nonresponsiveness in vitro and permanently accepted host-and donor-type skin grafts. Second donor-type skin grafts, transplanted 4 months later, were also indefinitely accepted. Third party transplants were rejected.
In the clinical setting, donor bone marrow (stem cells) can be obtained from a living-related donor or from a cadaveric donor at the time of organ procurement. The Pittsburgh group of Starzl recently reported their preliminary results combining high-dose donor bone marrow (3.10 8 /kg) with solid organ (kidney, liver, heart) and cell (pancreatic islet) transplantation without pretransplant radiation or other cytoreduction therapy. [16] [17] [18] [19] They suggest that simultaneous infusion of donor bone marrow at the time of whole organ transplantation leads to augmentation of microchimerism without the risk for GVHD. [18] [19] [20] However, patients are still receiving immunosuppressive drugs. Burke et al 21 also initiated donor bone marrow infusion as an adjuvant to quadruple immunosuppression for the solid organ kidney/pancreas transplant protocol. Preliminary results demonstrated a higher degree of chimerism in the group receiving bone marrow. Longterm acceptance of renal allografts and multilineage chimerism were demonstrated after administration of donor bone is more immunogenic than any other graft type, 22 we suggest clonal antibody (mAB) injections can replace thymic irradiation to that our well-tolerated method can be used for donor-specific allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell tolerance induction in organ transplantation. mABs and 3-Gy whole body irradiation. Transplantation 61:469, 1996 ACKNOWLEDGMENT 9. De Vries-van der Zwan A, Besseling AC, Kievits F, van We thank T. Jansen Hendriks for performing the murine experi-Twuyver E, de Waal LP: Anti-CD3 treatment facilitates engraftment ments, Drs M.A. van der Pol for technical assistance, and S.S. Weinof full H-2 disparate donor bone marrow cells and subsequent skin allograft tolerance. 
